T he ability to sense and respond to force is a fundamental feature observed across all scales of biology, from tissues 1,2 to cells 3, 4 and to individual molecules [5] [6] [7] [8] . Muscle contraction is a classic example in which tension sensing of the tissue 9 has its roots in the individual molecular motors working in every muscle cellthe myosin molecule.
The detachment rate is a key kinetic parameter describing myosin's actin-activated ATPase cycle because it determines the time myosin is bound to actin in a force-producing state. Notably, this rate depends on the force (load) against which myosin works, as demonstrated in single-molecule optical trap experiments with cardiac 10, 11 , skeletal 12 , smooth 13 , and nonmuscle myosins [14] [15] [16] . The load-dependent detachment rate (k det (F)) is a fundamental characteristic of every individual myosin molecule. As such, it determines whether a nonmuscle myosin is a force sensor (myosin Ib) or a transporter (myosins V and Ic), while for muscle myosins, it defines the identity of the particular muscle (skeletal, cardiac, or smooth). Even within a particular muscle type, different isoforms have different load-dependent kinetics adapted to their specific function [17] [18] [19] . For instance, the beta isoform of cardiac muscle myosin is slower but has higher load-bearing ability than the alpha isoform 20 , consistent with its dominant presence in the ventricles rather than the atria of the heart 21 . The cardiac myosin identity is so specifically tuned that the relative composition of the alpha and beta isoforms changes in the failing heart 21 . Furthermore, replacement of one by the other had a detrimental effect in transgenic mice subjected to cardiovascular stress 22 . Thus, it is apparent that significant differences in the amino acid sequences of different myosin types dramatically change k det (F) to accommodate their molecular functions. However, it is not known whether small perturbations, such as disease-causing mutations and small-molecule drugs, can control and alter the k det (F) in any specific myosin. Here we address this question by measuring the effects of various small perturbations on the load-dependent kinetics of human β -cardiac myosin. Measurement of k det (F) of individual striated-muscle myosin molecules under physiological (~2 mM) ATP conditions is challenging due to their short binding lifetime.
Existing techniques, while able to measure k det (F), require fast feedback and/or are not efficient at obtaining a large number of events. In contrast, harmonic force spectroscopy (HFS) presents a simple and efficient solution without the need for feedback 11 . Here we first demonstrate the robustness of the HFS method by measuring k det (F) for a population (N = 36) of single molecules of a truncated recombinant human β -cardiac subfragment-1 (short S1 or sS1, residues 1-808; Supplementary Fig. 1 ), the motor domain of the myosin responsible for force production in the ventricles of the heart (hereafter referred to as myosin). The efficiency of this method allowed us to tackle the aforementioned question: how is myosin's load-dependent kinetics controlled and affected by various biologically relevant perturbations? We tested the extent to which smallmolecule compounds affect k det (F). These compounds include both allosteric activators and an inhibitor of cardiac myosin, including the potential heart failure drug omecamtiv mecarbil (OM) 23 , and the potential active-site therapeutic 2-deoxy-ATP (dATP) 24, 25 . Next, we introduced mutations into β -cardiac sS1 that cause hypertrophic (HCM: D239N and H251N) or dilated (DCM: A223T, R237W, and S532P) cardiomyopathies and measured their effects on k det (F). We show that the effects of mutations can be reversed by adding the appropriate small-molecule compounds. In addition, we further investigated the mechanism of one of the compounds, OM, by measuring its dose-dependent effect on the detachment kinetics of myosin. Finally, our findings provide a new single-molecule-level understanding of cardiac myosin's power production under these various perturbations.
Articles NaTure STruCTural & MOleCular BIOlOgy apply a load 10, 12, 13, 26 , HFS does not. Oscillation serves two essential purposes: (i) a range of mean loads, both positive and negative, is automatically applied over the course of many events by virtue of the randomness of where myosin initially attaches to actin ( Fig. 1a and see also Supplementary Note); and (ii) oscillation allows us to detect short binding events of cardiac myosin to actin, which were previously more difficult to detect than longer events. In the unattached state, the dumbbell oscillates with phase π /2 radians ahead of the stage due to fluid motion, and in the attached state, the dumbbell oscillates in phase and with larger amplitude due to stronger association with the oscillating stage (Fig. 1b) . Therefore, events are detected automatically based on a simultaneous increase in oscillation amplitude above a threshold and a decrease in phase below a threshold (Fig. 1b) . In this way, HFS enables detection of short binding events (> 5 ms, one period of stage oscillation) under load regardless of the length of an event.
In the analysis of time-trace data for a single myosin molecule, binding events are first detected, each defined by the duration, t s , and mean force, F (Fig. 1c) . Events are then binned in force increments of ~1 pN so that the detachment rate for each bin, k det (F), can be calculated by a maximum likelihood estimation (MLE) on the exponentially distributed bound times (Fig. 1c) . Since the load experienced by myosin during an event is sinusoidal, with amplitude Δ F and mean F, the dependence of the detachment rate k det on force is given by the Arrhenius equation with a harmonic force correction:
e xp (1)
where k 0 is the rate at zero load, δ is the distance to the transition state of the rate-limiting step in the bound state (a measure of sensitivity to force), k B is the Boltzmann constant, T is temperature, and I 0 is the zeroth-order modified Bessel function of the first kind (to correct for the harmonic force). This equation is fitted to the Over the course of many individual events, a range of forces with mean F 1 (calculated as x 1 multiplied by the trap stiffness) is automatically applied as myosin attaches randomly along actin to experience both positive (resistive) and negative (assistive) loads 11 . Three events are outlined: F 1 > 0, F 1 ~ 0, and F 1 < 0. Each event experiences the oscillatory force with mean F 1 and amplitude Δ F 1 , calculated as the amplitude Δ x 1 multiplied by the trap stiffness. Force F in equation (1) is calculated as the sum of F 1 and F 2 from the second trapped bead, and the force amplitude Δ F is calculated as the sum of Δ F 1 and Δ F 2 (~3-4 pN). c, All events (N = 729) for one example molecule. Duration of event (t s ) is plotted against force. Events binned by force (dashed outline) have exponentially distributed binding times, from which the detachment rate at that force is determined by MLE (inset). The error on the rate is calculated from the variance of the MLE as the inverse Fisher information. d, The Arrhenius equation with harmonic force correction (equation (1)) is fitted to the detachment rates at each force to yield the load-dependent kinetics curve for one molecule. For this molecule, the rate at zero load k 0 = 84 ± 4 s −1
, and the distance to the transition state (a measure of force sensitivity) δ = 1.43 ± 0.07 nm. Errors on k 0 and δ are from the covariance matrix (inverse Fisher information matrix) for the parameters. e, k 0 and δ for all molecules measured (N = 36). Their weighted means, k 0 = 102 ± 4 s −1 and δ = 1.31 ± 0.03 nm, are shown as horizontal lines with s.e.m. in gray. f, Loaddependent kinetics curves for all molecules measured (gray), each described by a (k 0 , δ) pair in e. Individual data points, as in d, are not shown for clarity. The curve corresponding to the weighted means of k 0 and δ is shown in black. All experiments were done at saturating (2 mM) ATP.
detachment rates k det (F) with the parameters k 0 and δ to obtain the loaded curve for a single myosin molecule (Fig. 1d) .
Measurements of a population (N = 36) of single molecules of human β -cardiac myosin yielded the mean values k 0 = 102 ± 4 s −1 and δ = 1.31 ± 0.03 nm ( ± s.e.m.; Fig. 1e,f) , consistent with previous studies 10, 11 . The HFS method produces a load-dependent curve for each molecule rather than one from events aggregated across multiple molecules, thereby providing the distribution of the population and revealing inherent molecule-to-molecule differences (Fig. 1e,f) .
Allosteric effectors of human β-cardiac myosin slow down ensemble actin-sliding velocity. We investigated four allosteric activators (A2876, C2981, D3390, and OM), one allosteric inhibitor (F3345), and the active-site substrate dATP as small-molecule effectors of cardiac myosin (Fig. 2a) . dATP, a potential heart failure . b, Dose-dependent effects of the compounds on the actin-sliding velocity of human β -cardiac myosin. Velocities are normalized to the value at zero compound concentration. Error bars represent s.e.m. between two experiments, each tracking ~400 to ~1,900 actin filament movements; note that some data points have error bars smaller than the displayed point. Curves are four-parameter logistic fits. . 1 ) across the plots. For dATP, 2 mM dATP was used in place of ATP. All other conditions used 2 mM ATP, 2% DMSO, and 25 µ M compound. Two-tailed unequal variances t tests were performed on dATP vs. ATP, DMSO vs. WT, and compounds vs. DMSO. **P < 0.001, ***P < 0.0001. For detailed values, see Table 1 and Supplementary Table 1 , acts in place of ATP and has been shown to enhance cardiac myosin's ATPase activity 25 . A2876, C2981, and D3390 were derived from hits discovered from an ATPase screen using bovine cardiac subfragment-1 and regulated thin filaments (purified bovine actin, tropomyosin, and troponins C, I, and T), and F3345 was derived from a hit discovered from an ATPase screen using bovine myofibrils, all by MyoKardia, Inc. OM, an investigational drug in phase III clinical trials for heart failure 23, 27 (GALACTIC-HF, ClinicalTrials.gov NCT02929329), has been proposed to increase ensemble force by increasing myosin's duty ratio, the fraction of time spent in the strongly bound, force-producing state 20, [28] [29] [30] . The rate of ADP release normally determines the strongly bound state time, but OM was found to delay the power stroke 30 without affecting this rate 23, [28] [29] [30] . To clarify OM's mechanism of action, we used HFS to directly measure whether the drug causes a single cardiac myosin molecule to stay bound to actin longer.
To determine the effects of the compounds when a single myosin molecule has a compound bound, a saturating concentration of compound was required. To determine this concentration, we measured the dose-dependent effects of the compounds on the actinsliding velocities of human β -cardiac myosin in an in vitro motility assay 20, 31 . Unexpectedly, both activators and inhibitors slowed down velocities (Fig. 2b) . OM had the most dramatic effect, with a median effective concentration of ~0.1 µ M, in close agreement with previous measurements 20, 28, 29 . Activator A2876 had no effect on the velocity beyond that from DMSO alone (see Methods). Guided by the motility measurements, we performed subsequent single-molecule experiments that involve allosteric effectors at a concentration of 25 µ M in 2% DMSO.
Small-molecule compounds modulate the load-dependent kinetics of single molecules of human β-cardiac myosin. We measured the effects of the small-molecule compounds on the load-dependent detachment rates of single molecules of human β -cardiac myosin using HFS (Fig. 3) . For clarity, we present only the average curve for each condition in Fig. 3b (for ), while δ did not change significantly (dATP: δ = 1.5 ± 0.1 nm versus ATP: δ = 1.31 ± 0.03 nm; P = 0.13), in close agreement with experiments performed using bovine cardiac heavy meromyosin (HMM; Tomasic, I., Liu, C., Rodriguez, H., Spudich, J.A. and Bartholomew Ingle, S.R., manuscript in preparation). Compound A2876 had no effect beyond that from DMSO. This result is consistent with observations that A2876 has no effect on the actin-activated ATPase of purified bovine cardiac myosin and actin, but only activates myosin's ATPase activity in the presence of regulated thin filaments, suggesting possible interactions with the tropomyosin-troponin complex (Anderson, R., MyoKardia Inc., unpublished results). The activators C2981, D3390, and OM decreased k 0 dramatically (C2981:
), while also decreasing (C2981: δ = 0.79 ± 0.05 nm, D3390: δ = 0.93 ± 0.03 nm, OM: δ = 0.26 ± 0.05 nm; Fig. 3a) , resulting in much lower and flatter curves that were less sensitive to force (Fig. 3b) . These three activators probably interacted directly with myosin, and lowering of both k 0 and δ may be a general characteristic of myosin-associated activators. In contrast, the inhibitor F3345 decreased the detachment rate (k 0 = 36 ± 2 s ) without changing the force sensitivity (δ = 1.27 ± 0.06 nm), suggesting a possible mechanism of action distinct from the activators. Taken together, we found that small-molecule effectors can modulate the detachment rate and load sensitivity of cardiac myosin to various degrees.
Cardiomyopathy-causing mutations alter the load-dependent kinetics of single molecules of human β-cardiac myosin. We next measured the effects of various cardiomyopathy-causing mutations on the load-dependent detachment rates of single molecules of human β -cardiac myosin using HFS (Fig. 4, Supplementary Figs (D239N and H251N) were previously found to cause myosin to have higher actin-sliding velocities in the in vitro motility assay 32 . Consistent with their hyperactivities, these two HCM mutants exhibited faster detachment rates than the wild-type (WT) protein at the single-molecule level (D239N: k 0 = 140 ± 3 s ) and had minimal effects on force sensitivity (D239N: δ = 1.40 ± 0.03 nm, P = 0.04; H251N: δ = 1.53 ± 0.08 nm, P = 0.02). Of the three DCM mutations we studied, A223T did not change the detachment kinetics compared to WT (k 0 = 104 ± 4 s , P = 0.17; δ = 1.48 ± 0.09 nm, P = 0.13), R237W increased the rate without changing force sensitivity (k 0 = 155 ± 15 s , P = 0.004; δ = 1.25 ± 0.06 nm, P = 0.43), and S532P decreased the rate slightly without changing force sensitivity (k 0 = 80 ± 8 s , P = 0.02; δ = 1.37 ± 0.06 nm, P = 0.57). Thus, point mutations that cause disease can indeed alter the load-dependent kinetics of cardiac myosin to various degrees, but whether the mutation is clinically HCM or DCM does not dictate the direction of the change (Supplementary Fig. 6 ). Notably, the DCM mutants R237W and S532P both had greater molecule-to-molecule variabilities in k 0 compared to WT and other mutants ( Fig. 4a and Supplementary  Fig. 5 ), suggesting that these mutations may cause a disruption in protein folding that affects individual myosin molecules in a population to different extents.
The effects of cardiomyopathy-causing mutations can be reversed by appropriate small-molecule compounds. If an effect of a disease-causing mutation is to alter the detachment rate, then we hypothesized that a small-molecule compound with the opposite effect on WT myosin would reverse the alteration caused by the mutation, provided the mutation does not interfere with the action of the compound. To test our hypothesis, we first measured the effects of the inhibitor F3345 on the load-dependent kinetics of each of the two HCM mutants. As expected, we observed a dramatic decrease in the detachment rates of both (D239N + F3345, k 0 = 24 ± 2 s Table 1) . Next, since the DCM mutant R237W had a faster detachment rate than WT, we applied the activator OM and found a similarly dramatic reversal (k 0 = 8 ± 1 s Table 1) . Finally, since S532P had a slower detachment rate than WT, we found that replacement of ATP with dATP reversed the mutation's effect (k 0 = 170 ± 6 s
−1
). Since saturating compound concentrations (25 µ M allosteric effectors or 2 mM dATP) reversed the effects of mutations beyond WT levels (Fig. 4) , we expect that appropriate lower concentrations can adjust the detachment kinetics of mutants to match that of WT myosin if desired.
Dose-dependent effects of OM on detachment kinetics of individual myosin molecules.
We next investigated the dose-dependent effects of OM on single cardiac myosin molecules' detachment kinetics. Plasma concentrations of OM in patients in clinical trials are ~500 nM 27 . Therefore, we used HFS to measure the bound times of myosin in the presence of 30 nM to 25 µ M OM. We found that with OM, the bound times within a force bin followed a double exponential distribution (Fig. 5a,b) instead of a single exponential distribution, as observed under all other conditions ( Fig. 1c and Supplementary Fig. 7 ). The presence of two populations suggests that, for each event, myosin either had or did not have OM bound; the kinetics of OM binding and unbinding myosin were slow enough that a single exponential distribution with an average rate was not observed 33 . These data are consistent with two possible models (Fig. 5d) . In both models, a fraction, A, of events does not have OM bound to myosin, and thus undergoes detachment from actin via rate k 1 , presumably the same rate k det (F) measured for myosin in the absence of compounds. The remaining 1 -A events that do have OM bound undergo detachment from actin via one (Model 1) or two (Model 2) steps. In Model 1, the OM-bound myosin detaches from actin at rate k 2 . In Model 2, OM must first unbind myosin at rate k 2 before the rest of the actin-bound state (power stroke, ADP release, ATP binding) proceeds at rate k 1 .
Event lifetimes were MLE-fitted using MEMLET 34 to a double exponential distribution whose two characteristic rates k 1 and k 2 followed equation (1) independently (see Methods). The fitted variables are k 01 , δ 1 , k 02 , δ 2 , and A. The analysis process is illustrated for the 300 nM OM case in Fig. 5a -c. As expected, whereas the overall rate, k overall , from fitting to a single exponential distribution had k 0 and δ values that decreased as OM concentration increased, the parameters describing each population (k 01 , δ 1 , k 02 , and δ 2 ) were independent of OM concentration (Fig. 5e,f) . The values of k 01 and δ 1 (k 01 = 105 ± 6 s −1 ; δ 1 = 1.2 ± 0.1 nm) are consistent with the detachment kinetics of WT myosin from actin ( Fig. 1e and Table 1 ). The interpretation of k 02 and δ 2 (k 02 = 16 ± 1 s −1 ; δ 2 = 0.48 ± 0.03 nm) differ between the two models. In Model 1, they are interpreted as the slow and slightly load-dependent detachment kinetics of OM-bound myosin from actin. In Model 2, they are interpreted as the detachment kinetics of OM from myosin. In the latter case, the nonzero positive δ 2 suggests that the unbinding of OM is also slightly force-sensitive: a force in the direction of the power stroke likely destabilizes OM's binding pocket 35 , speeding up its release. The fraction of OM-bound events (1 -A) increased with OM concentration (Fig. 5g) . A fit to the Michaelis-Menton equation gives an apparent K d = 0.31 ± 0.05 µ M, in perfect agreement with the affinity of OM to myosin's pre-power stroke state, as measured by isothermal titration calorimetry 35 . Notably, this fraction . 1 ) across the plots. Addition of allosteric compounds (F3345 to D239N and to H251N; OM to R237W) were in presence of 2% DMSO. Two-tailed unequal variances t tests were performed on mutants vs. WT and mutants + compounds + DMSO vs. mutants + DMSO, or S532P + ATP vs. S532P + dATP. *P < 0.05, **P < 0.001, ***P < 0.0001. For detailed values, see Table 1 and Supplementary Table 1 (1 -A) did not reach 1 even at saturating OM concentrations; ~40% of events were able to escape the slow pathway involving OM ( Fig. 5g and Supplementary Fig. 7 ). This result suggests that there must be a state in which myosin either does not bind the drug, or binds it in a different manner such that release of the drug is fast. The above dosage analysis reveals OM's mechanism of modulating cardiac myosin's detachment kinetics at both high and low clinically relevant concentrations. Taken together, we found that both small-molecule effectors and disease-causing mutations in human β -cardiac myosin can independently and in combination modulate the behavior of single myosin molecules under load. This allows fine-tuned control over the fundamental load-dependent kinetics curve that defines cardiac myosin.
Single molecule load-dependent kinetics is the basis of the ensemble force-velocity relationship in β-cardiac myosin. In ensemble motility, the sliding velocity of an actin filament is limited by how fast the attached myosin molecule can let go of it, i.e., the detachment rate of myosin 36 . Given enough heads on the surface (1) as determined from all events of the 300-nM OM dataset). The overall rate (black) is obtained by fitting a single exponential distribution. When the double exponential distribution is used, the two fitted rates, k 1 (blue) and k 2 (red), each follow equation (1) . The curves are obtained from an MLE on all events without binning by force. Independently, the rates at each force are obtained by a MLE on events binned by force (as in b) and plotted as data points. Inset shows a zoomed-in view. See Methods for details. d, Kinetic models of OM's action on single myosin molecules. The fraction, A, of events in which OM is not bound to myosin (M) undergo detachment from actin (a) at rate k 1 , the load-dependent detachment rate of myosin as measured earlier in this work (top). In the fraction 1 -A of events in which OM is bound (indicated by periods) to myosin, either OM-bound myosin detaches from actin at rate k 2 (Model 1) or myosin releases OM first at rate k 1 and then detaches from actin at rate k 1 (Model 2). e,f, k 0 and δ at different concentrations of OM for the overall detachment (black) and its fast (blue) and slow (red) components, obtained by MLE on all events from 6-9 molecules for each concentration of OM (as in c). and a relatively short tether, as is the case in our motility assays with cardiac sS1, velocities are detachment-limited rather than attachment-limited 37 . Therefore, as expected here, ensemble velocities measured by the in vitro motility assay were linearly related to the single molecule detachment rate, k 0 , with a slope of 8.9 nm and R 2 = 0.81 (Fig. 6a) . In contrast, linear regression of velocity versus attachment rate, k attach (see "Discussion" for calculation of k attach ), gave R 2 = 0.35 ( Supplementary Fig. 8 ). In simplest terms, since unloaded velocity v = d/t s = d × k 0 , where d = step size and t s = strongly bound state time, the slope obtained from the linear fit can be interpreted as the effective step size of myosin in the ensemble. This effective step size (8.9 nm) is greater than the value from direct step-size measurements on single cardiac myosin molecules (~7 nm) 10, 38, 39 because the nonzero load-dependence (δ) of cardiac myosin results in faster detachment rates in the ensemble 40 . Notably, the activators and HCM mutants lie on or above the fitted line, while the inhibitor F3345 and DCM mutants lie below it ( Fig. 6a ; see also Supplementary Note). This presents a possible distinction between the two groups, in which activating perturbations produce greater coordinated movement in the ensemble than predicted by singlemolecule detachment rates, while inhibitory perturbations result in less enhancement.
In addition to k 0 , our data revealed differences in force sensitivity (δ) under different perturbations to cardiac myosin at the single-molecule level (Figs. 3a and 4a) . Therefore, we asked whether changes to the force sensitivity of single molecules result in similar findings on the ensemble level. We measured ensemble force sensitivity by a loaded in vitro motility assay 20 . In this assay, utrophin on the surface binds to actin to provide the load that myosin must overcome in moving actin filaments. Increasing the concentration of utrophin increases load and thus decreases actin-sliding velocity. This gives an ensemble force-velocity curve (Supplementary Fig. 9 ). The concentration of utrophin, K s , required to reduce velocity by half is therefore a measure of force sensitivity. As expected, we found that K s was inversely proportional to δ (Pearson correlation coefficient = -0.94; Fig. 6b and Supplementary Fig. 9 ). As single myosin molecules became insensitive to load (smaller δ), such as in the presence of the activators OM, C2981, and D3390, higher concentrations of utrophin were required to reduce the ensemble velocities by a half.
In conclusion, we have found that the load-dependent kinetics inherent to each molecule of cardiac myosin can be modulated by various small-molecule compounds and mutations. This singlemolecule characteristic underlies the force-velocity relationship exhibited in ensemble.
Discussion
Different types of myosin have dramatically different scales of the load-dependent detachment rate. The type I 15, 16 , type V 14 , smooth 13 , and β -cardiac 10,11 isoforms have distinct rates and force sensitivities ranging from k 0 ~1 to 100 s −1 , and δ ~1 to 12 nm. Here, armed with the efficient HFS method, we explored whether changes to the detachment kinetics can be made via small perturbations in the form of small-molecule compounds and cardiomyopathy-causing single missense mutations in human β -cardiac myosin. The results lie across the spectrum: not all perturbations changed the single molecule load-dependent detachment rate (activator A2876, DCM mutant A223T), while the rest modulated the curve to various extents (Figs. 3 and 4 and Supplementary Fig. 6 ). Modulation was seen in the rate at zero load (k 0 ~10 to 170 s ) and/or force sensitivity (δ ~0.2 to 1.5 nm). Furthermore, the effects of mutations could be reversed by an appropriate compound (Fig. 4) . Thus we have observed fine tuning of the load-dependent kinetics on single molecules of cardiac myosin. In oversimplified terms, we can control cardiac contractility at the single molecule level.
Perturbations to myosin change its load-dependent detachment rates through different steps in the ATPase cycle. Any step in the strongly bound state may be affected by the compounds and mutations. ADP release is the canonical rate-limiting step of the strongly bound state for WT cardiac myosin. This is likely the acted-upon step for dATP, inhibitor F3345, and mutations, since the transitionstate distance (δ) for those conditions remained close to that of unperturbed WT myosin (Figs. 3a and 4a and Table 1 ). Furthermore, it has been shown, by stopped-flow experiments of bovine cardiac HMM, that the faster nucleotide release rate when dATP is used in place of ATP matches the detachment rate measured on single molecules (Tomasic, I., Liu, C., Rodriguez, H., Spudich, J.A. and Bartholomew Ingle, S.R., manuscript in preparation). For the activators C2981, D3390, and OM, the significantly smaller δ values ( Fig. 3a and Table 1 ) suggest a new rate-limiting step. Future kinetic studies can illuminate the precise steps at which they act.
For OM, it has been shown that the drug stabilizes the pre-power stroke state in which myosin is ready to bind to actin 35 , accelerates phosphate release 23, 28, 30 , and then delays the power stroke while myosin is in the actin-bound state 30 . Structural data show that the OM binding pocket is incompatible with the post-stroke state, which suggests that OM unbinds before the stroke 35 , thus leaving the ADP release rate unaffected 23, [28] [29] [30] . In our study, we measured a large increase in the lifetime (1/k det ) of the bound state 41, 42 , consistent with the previously observed delay in power stroke. We determined that this delay can be attributed to the off rate of OM-bound myosin from actin (one-step model) or the off rate of OM from myosin (two-step model) for events in which myosin has the drug bound at the start (see also Supplementary Note). Our data are consistent with and cannot distinguish between the two models. But while this paper was in revision 41 , new data have been presented that lend support to the one-step model 42 .
Unlike an ultrafast feedback trap 12 , HFS cannot, yet, measure the power stroke. Thus, in the case of OM, we cannot observe the exact proposed sequence of events from myosin binding to actin, delay, stroke or no stroke (depending on the model), and finally detachment from actin. Despite the limitations of HFS in distinguishing different phases of the bound state, it can be argued that wherever in this state an effector acts, the same result is achieved: the overall bound time is changed, and it is this overall bound time that limits ensemble velocity and determines force production.
Indeed, we found a strong linear relationship between singlemolecule detachment rate, k 0, and ensemble velocity (Fig. 6a) . A linear relationship has also been observed between the ADP release rate, which limits detachment, and the unloaded shortening velocity of skeletal muscle fibers 17, 18 . In addition, changes to the force sensitivity, δ, of individual molecules are mirrored at the ensemble level (Fig. 6b) . Thus, different mechanisms of changing the detachment rate and its force dependence inherent to a single molecule can lead to the same ensemble force-velocity behavior.
We have found that activating and inhibitory perturbations can increase, decrease, or not affect the detachment rate (Figs. 3 and 4 and Supplementary Fig. 6 ). While this may be expected since compounds and mutations can act via different mechanisms, the question remains: what distinguishes one group from the other? A heart containing an HCM mutation (for example, H251N) undoubtedly is hypercontractile 43 compared to one bearing a DCM mutation (for example, R237W), despite both having faster detachment rates. Given knowledge of their load-dependent kinetics, we believe that the answer lies in an assessment of the resulting duty ratio, average force, and power output.
Implications of single-molecule load-dependent kinetics on
power production by β-cardiac myosin. The duty ratio is the fraction of time that myosin spends in the strongly bound, force-producing state. It is a function of load force F (see Methods):
attach attach det where k attach describes the lifetime of the unbound state. k attach can be calculated by
where k cat is the overall cycle rate measured by steady state ATPase. The average force a single molecule produces can then be calculated given the duty ratio:
av Finally, the average power produced by a single myosin is calculated by:
av det where d is the step size. The values of all variables in these equations are known (Table 1) : k det (F) given by equation (1) is measured by HFS in this study, k cat is measured in an actin-activated ATPase assay in this study (Table 1 and Supplementary Fig. 10 ) and others 20, 32, 44 , and d is taken to be 7 nm (see Supplementary Note and Methods). Consistent with previous and physiological expectations [28] [29] [30] 35, 44, 45 , we find that the duty ratios, average forces, and average powers of the activators and HCM mutations are, in general, greater than those of the inhibitor and DCM mutations (Fig. 7) . Here agian, HCM and (2)-(5). All curves are calculated using values of detachment rate kinetics (k 0 , δ), k cat , and k attach given in Table 1 . Black, WT; gray, DMSO; blue, HCM or activators; red, DCM or inhibitor.
activators segregated from DCM mutations and inhibitors (Fig. 7c) . The activator OM is of particular interest, given its pharmacokinetic characteristics that are advantageous for cardiac activation clinically, and for targeting the contractile apparatus directly without impacting calcium fluxes that can lead to pleiotropic effects 27 . Its mechanism of action as an established activator of heart function is proving to be more nuanced than initially thought 23 . Two key effects underlie its clinically activating function: (i) stabilization of the pre-stroke state increases the number of myosin heads ready to bind to actin 35 ; and (ii) once bound to actin, the heads stay on ~6× longer (Figs. 3 and 5) , greatly increasing the duty ratio (Fig. 7a) . The combination of these two effects, especially the latter, is proposed to prolong the activation of the thick 46, 47 and thin 42 filaments, which in turn prolongs contraction 23, 27 by allowing additional heads to bind. These molecular findings help explain the effects of OM observed at the organ level: the predicted higher average force (Fig. 7b) , due to a great number of actin-bound heads (Fig. 7a) , is consistent with an increase in peak time-dependent elastance of the left ventricle (a measure of LV contractility) and stroke volume; the proposed prolonged activation of the thick and thin filaments, due to the slower detachment kinetics, is consistent with a longer time to a higher maximum pressure and a longer time in systole 23, 27 . Our dosage analysis of OM revealed that a common molecular mechanism underlies the drug's effect across a large range of concentrations, including clinically relevant doses (~500 nM) 27 ( Fig. 5) . At the same time, the sensitivity of myosin's power production to the concentration of OM (Fig. 7c) illustrates the importance of the therapeutic window. OM's significant lengthening of the time that myosin is bound to actin during a prolonged systole explains both its clinically activating function (as discussed above) at therapeutic doses and its documented ischemic effect at high doses (> 3 µ M) from excessively prolonged systole 27 . A careful balance of OM's slow kinetics with its activating function to increase the duty ratio must be and is considered in clinical trials. Finding the optimal degree of alteration in myosin function is critical in modulating ventricular function as a whole.
The k cat term in the above equations encapsulates the term N a , the number of available heads. The myosin 'mesa' is a relatively flat surface on the motor domain that is involved in the interaction of folded-back heads with the proximal tail, forming the so-called interacting heads motif (IHM), and that harbors many HCM mutations 48 . Mutations on the mesa and compounds that regulate IHM may change N a , thus changing k cat 46, [49] [50] [51] [52] . While the current study does not assess changes to k cat through N a , because the sS1 construct lacks the tail domain, future studies may do so using HMM. In addition, other factors that build a more complex, comprehensive system (for example, regulated thin filament, myosin binding protein C) can also change k cat through modulation of IHM.
Given the above considerations, we propose a model in which activating versus inhibitory perturbations of cardiac myosin are discriminated by their effect on duty ratio, average force, and ultimately, average power (Fig. 8) . Neither the detachment rate nor the overall cycle rate can distinguish by themselves the two types of perturbations. When both are taken into account by the duty ratio, force, and power, then we see the physiologically expected outcome: activating perturbations are hypercontractile, while inhibitory ones are hypocontractile. To build a comprehensive understanding of the molecular mechanism underlying muscle contraction, these calculations take into consideration all the parameters of power production: load force (F), load-dependent detachment rate (k det (F)), overall cycle rate (k cat ), number of available heads (N a , included in k cat ), and step size (d).
Recent studies of several HCM mutations (R453C 38 , R403Q 39 , and three in the converter domain 53 ) found variable changes to parameters of force production (without k det (F) measurements) that do not clearly point to a hypercontractile phenotype. Armed with the efficiency of the HFS method, future studies measuring k det (F) for these mutants and others will determine whether molecular hyper-and hypocontractility are indeed the respective underlying effects of HCM and DCM.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41594-018-0069-x.
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Methods
Reagents. Small-molecule compounds were a generous gift from MyoKardia, Inc. (South San Francisco). They were stored at 10 mM in DMSO at 4 °C.
Protein preparation. Construction, expression, and purification of the WT and mutated recombinant human β -cardiac myosin sS1s are described in detail elsewhere 32, 38 . Briefly, a truncated version of MYH7 (residues 1-808), corresponding to sS1, with either a C-terminal enhanced green fluorescent protein (eGFP) or a C-terminal eight-residue (RGSIDTWV) PDZ-binding peptide, was coexpressed with myosin light chain 3 (MYL3), encoding human ventricular essential light chain (ELC), and containing an N-terminal FLAG tag (DYKDDDDK) and tobacco etch virus (TEV) protease site in mouse myoblast C2C12 cells using the AdEasy Vector System (Obiogene Inc.). The myosin heavy chain with its associated FLAG-tagged ELC was first purified from clarified lysate with anti-FLAG resin (Sigma). After cleaving off the FLAG tag with TEV protease, the human β -cardiac sS1 was further purified using anion exchange chromatography on a 1-mL HiTrap Q HP column (GE Healthcare). Peak fractions were eluted with column buffer (10 mM imidazole, pH 7.5, ~200 mM NaCl, 4 mM MgCl 2 , 1 mM DTT, 2 mM ATP, and 10% sucrose) and concentrated by centrifugation in Amicon Ultra-0.5 10-kDa cutoff spin filters (EMD Millipore) before being stored at -80 °C. The purity of the protein was confirmed using SDS-PAGE (Supplementary Fig. 1 ). Frozen proteins exhibited similar activities in the motility, single-molecule, and ATPase assays compared to their fresh counterparts, as seen in previous work 53 .
Deadheading myosin. Myosin protein used for motility and trap experiments was further subjected to a 'deadheading' procedure to remove inactive heads. Myosin was mixed with 10× excess of unlabeled F-actin on ice for 5 min, followed by addition of 2 mM ATP for 3 min, then centrifuged at 95 K rpm in a TLA-100 rotor (Beckman Coulter) at 4 °C for 20 min. The supernatant was collected for use in the motility and trap experiments. Myosin used in the ATPase assay was not subjected to deadheading.
Actin-activated ATPase. Purified bovine cardiac G-actin, provided by MyoKardia, Inc., was freshly cycled to F-actin by extensive (four times over 4 d) dialysis in ATPase buffer (10 mM imidazole, pH 7.5, 5 mM KCl, 3 mM MgCl 2 , and 1 mM DTT) to remove any residual ATP, up to a week before each experiment. The monomeric concentration of F-actin was determined by measuring the absorbance of a serial dilution of the actin in 6 M guanidine hydrochloride both at 290 nm with an extinction coefficient of 26,600 M cm −1 in a spectrophotometer (NanoDrop). Full-length human gelsolin was added to actin at a ratio of 1:1,000 to reduce the viscosity of the actin and thereby decrease pipetting error at higher actin concentrations without affecting the ATPase activity 38 . The steady-state actin-activated ATPase activities of freshly prepared human β -cardiac sS1-eGFP were determined using a colorimetric readout of phosphate production 54 . In this assay, reactions containing sS1 at a final concentration of 0.01 mg mL −1 , 2 mM ATP or dATP, and actin at concentrations ranging from 2 to 100 μ M were performed at 23 °C with plate shaking using a microplate spectrophotometer (Thermo Scientific Multiskan GO). Prior to the start of each reaction, sS1s were incubated on ice with 25 μ M of the indicated type of small molecule compound in 2% DMSO for 5 min. ATP or dATP was added at t = 0, and four additional timepoints up to 30 min were measured subsequently for each actin concentration. The rate of sS1 activity was obtained by linear fitting the phosphate signal as a function of time and converted to activity units using a phosphate standard.
A set of experiments measuring all conditions (dATP and compounds) on WT sS1-eGFP were performed on the same day that myosin was purified to ensure that conditions could be directly compared to each other without variation due to different protein preparations. Each experiment of each condition was performed in duplicates or triplicates. The error on each data point (ATPase activity at a certain actin concentration) represents the s.e.m. of the replicates. The MichaelisMenten equation was fitted to determine the maximal activity (k cat ) and the actin concentration at half-maximum (apparent K m for actin). Data from 1 d are shown in Supplementary Fig. 10a . The k cat values from each day's experiment are averaged and presented in Table 1 along with their s.e.m. values. Here we performed two sets of experiments using two protein preparations and a total of 5-7 replicates. Since each set of experiments measured all conditions on the same day using the same protein prep, we used paired t tests to test for significance (Table 1) . We also performed a Michaelis-Menten fit to the aggregated data from both days (Supplementary Fig. 10b ).
In vitro motility. The basic method followed our previously described motility assay with some modifications 31, 39, 53 . Dose-dependent change in unloaded velocity was observed by measuring actin velocities at 8-12 different concentration of each compound. Four different concentrations of a compound were tested on each motility slide, and 2-3 slides were analyzed simultaneously in each set of experiments to obtain full dose-titration curves. Normalization of velocity was done using the velocity of the WT control from the same set of experiments. For loaded in vitro motility assays, 2-4 different concentrations for each compound (including baseline controls) were chosen according to the dose-titration curve of unloaded velocity. For each compound concentration, the force-velocity curve was obtained by measuring actin velocities at 8-12 different concentrations of utrophin. Four different concentrations of utrophin were tested on each motility slide, and 2-3 slides were analyzed simultaneously in each set of experiments to obtain full force-velocity curves. Videos were analyzed using FAST (Fast Automated Spud Trekker), software that automates tracking of actin filaments for in vitro motility assays and analyzes the velocity of each filament in high throughput 20 . Velocities reported are mean velocity (MVEL) with 20% tolerance, as described previously 20 . Each experiment tracked ~400 to ~1,900 actin filament movements, and the same condition was repeated. For unloaded velocity, (mean ± s.e.m.) values from the two experiments are plotted against compound concentration (Fig. 2) . After myosin was attached to the motility surface and washed with BSA-containing assay buffer, a final solution was created that contained fluorescently labeled bovine actin, 2 mM ATP, an oxygen-scavenging system (0.4% glucose, 0.11 mg mL −1 glucose oxidase, and 0.018 mg mL −1 catalase), an ATP regeneration system (1 mM phosphocreatine (PCR), 0.1 mg/mL creatine phosphokinase (CPK)), and a designated concentration of compound in 0.5% DMSO. The myosin was incubated in the compound-containing final solution for at least 5 min before videos were taken. The amount of time the final solution was incubated in the chamber before videos were taken did not affect the velocity (data not shown). DMSO had minimal effect on velocity (2% DMSO had a 10% reduction in velocity). All experiments were performed at 23 °C.
Single-molecule measurements of load-dependent detachment rates. Measurements were performed using the harmonic force spectroscopy (HFS) method in a dual-beam optical trap 11 .
Sample chamber preparation. The sample chamber was built on a glass coverslip, spin-coated first with 1.6-µ m-diameter silica beads (Bang Laboratories) as platforms and then with a solution of 0.1% nitrocellulose and 0.1% collodion in amyl acetate. The flow channel was constructed by two double-sided tapes between a glass slide and the coverslip. Experiments were performed at 23 °C. The GFP antibody (Abcam ab1218), at a final concentration of ~1 nM, diluted in assay buffer (AB; 25 mM imidazole pH 7.5, 25 mM KCl, 4 mM MgCl 2 , 1 mM EGTA, and 10 mM DTT) was flowed into the channel to bind the surface for 5 min, followed by washing and blocking with 1 mg mL −1 BSA in AB (ABBSA) for 5 min. Deadheaded human β -cardiac myosin sS1-eGFP, diluted to a final concentration of ~10-50 nM in ABBSA, was flowed in next and allowed to saturate GFP antibody binding sites for 5 min. Then the unbound myosin was washed out with ABBSA. Lastly, the final solution was flowed in; this solution consisted of 2 mM ATP, 1 nM TMR-phalloidin-labeled biotinylated actin (cytoskeleton, ~1 biotin per monomer) filaments, an oxygen-scavenging system (0.4% glucose, 0.11 mg mL −1 glucose oxidase, and 0.018 mg mL −1 catalase), and 1-µ m-diameter NeutrAvidin-coated polystyrene beads (ThermoFisher) diluted in ABBSA. The chamber was sealed with vacuum grease. For experiments with 2-deoxy-ATP, 2 mM 2-deoxy-ATP was used in place of ATP. For experiments with other small-molecule compounds, ABBSA contained 2% DMSO and specified concentration of compound.
HFS experiments. Details of the technique have been presented elsewhere 11 . Two NeutrAvidin beads were trapped in two trap beams. The beads were moved in ~57 nm steps in a 9 × 9 raster scan using acousto-optic deflectors, while their displacements were recorded both in brightfield (in nm) and with quadrant photodiode (QPD) detectors (in voltage) to produce a voltage-to-nm calibration. The stiffness of each trap beam was calculated by the equipartition method and was typically ~0.07 pN nm −1 (right) and 0.09 pN nm −1 (left) in these experiments. After this calibration, an actin filament was stretched to ~5 pN pretension between the two trapped beads to form a 'dumbbell' . We sinusoidally oscillated the piezoelectric stage at 200 Hz with amplitude set at 50 nm. While the amplitude was set to 50 nm, the stage actually oscillated at ~30 nm due to the response of the stage at 200 Hz. The dumbbell was lowered near a platform bead to check for binding to a potential myosin on the platform, as indicated by large, brief increases in the position amplitudes of the trapped beads ('robust interactions') due to stronger association with the oscillating stage. Due to compliance, the dumbbell oscillated with amplitude ~15-25 nm during a binding event, which corresponds to a total force dF ~3-4 pN from the two traps. We typically explored ~5-10 platform beads before robust interactions were observed, suggesting that the GFP antibody and myosin concentrations used in this study resulted in sufficiently low numbers of properly oriented molecules on the surface such that events observed were likely due to a single myosin. Control experiments with GFP antibody only (without myosin) revealed that any interactions between the antibody and the dumbbell were not 'robust' as defined above; their amplitudes were small and the durations were very short, such that they would not pass the analysis detection criteria as detailed below. The positions of the trapped beads and the piezoelectric stage were recorded at a 50-kHz sampling frequency. We recorded data on each molecule for ~10 min and used each slide for 1.5-2 h. We did not observe the motor slowing down during the 10-min recording for one molecule nor for multiple molecules on one slide during a 2-h experiment, suggesting that the 2 mM ATP was not substantially depleted despite our foregoing an ATP regeneration system. HFS data analysis. The theory underlying the HFS method and its data processing details have been presented elsewhere 11 . In summary, in the unattached state, the dumbbell oscillates with phase π /2 radians ahead of the stage, due to fluid motion, while in the attached state the dumbbell oscillates in phase and with a larger amplitude due to stronger association with the stage. Therefore, events are detected based on a simultaneous increase in oscillation amplitude above a threshold (~15 nm) and a decrease in phase below a threshold (~0.5 rad) for at least one full stage oscillation period. Several additional event filters were applied to minimize false positives. The final number of events for each molecule ranged from ~300-1,000. For each event, the mean force due to each trap was calculated as the bead position averaged over the duration of binding multiplied by the trap stiffness. The total mean force on myosin is the sum of the two mean forces. A range of forces, both positive and negative, is automatically applied to myosin because binding can occur anywhere in the cycle of oscillation. Through this event detection algorithm, the mean force, amplitude of oscillation, and duration (F, Δ F, and t s ) of each event were obtained.
For each molecule, events were binned by force in ~1-pN increments, and a maximum likelihood estimation (MLE) of the geometric distribution (the discrete version of the exponential distribution) of bound times, with dead-time correction (5 ms), was performed for each bin to obtain the detachment rate for the mean force of the bin, k det (F). The error on k det (F) is calculated from the variance of the MLE as the inverse Fisher information. This results in a plot of k det (F) vs. F, on which we performed a weighted least-squares fit of equation (1) We also used MEMLET 34 to analyze a few molecules to compare the two analysis methods. The input data to MEMLET were the (F, Δ F, t s ) produced by the HFS analysis program. MEMLET does not require binning events in force. Instead, it produces the fitted variables k 0 and δ from an MLE fit of all events of one molecule to the geometric distribution, in which the rate parameter of the distribution is given by equation (1) . In the molecules we tested, MEMLET gave nearly identical k 0 and δ values. MEMLET uses bootstrapping to obtain the uncertainties of the fitted variables. The 68% confidence intervals obtained by MEMLET bootstrapping were very similar to the errors calculated by the inverse Fisher information matrix. The excellent agreement between these two analysis methods, one that bins in force and another that does not, was expected because the large number of events available through the HFS method minimizes the negative effects of binning 34 . Note, however, that bootstrapping 1,000 iterations required several minutes (up to ~1 h for more complex distribution functions such as ones used in the OM dosage analysis below), while calculation of errors from the Fisher information matrix used < 1 s. Fig. 5d , the distribution of bound times is given by According to Model 2, the distribution is given by where
Analysis of single-molecule OM dosage data. According to Model 1 in
Model 2's distribution is still a sum of two exponentials, as seen more clearly by redefining the coefficients: where
In MLE fitting, the actual function used is the discrete geometric rather than the continuous exponential distribution due to the requirements of HFS to bin durations in an integer number of stage oscillation periods 11 . In addition, the minimum detectable time (5 ms) is taken into account by a dead-time correction.
MEMLET uses the above probability distribution function to fit to the (F, Δ F, t s ) data, producing the five fitted parameters k 01 , δ 1 , k 02 , δ 2 , and A. Here the advantage of fitting without binning by force can be appreciated: the larger number of fit parameters gives rise to variability when fitting a subset of data in one force bin. For this same reason and for simplicity of analysis, rather than performing separate analyses on individual molecules (as we have done with all other compound and mutation conditions), we aggregated events from all molecules for each OM concentration before performing the MLE. Note that the slow and fast populations of events were observed for every single molecule; thus it is not the case that some molecules simply do not bind OM. The curves in Fig. 5c and all data in Fig. 5e-g use values of the five parameters from fitting without binning by force. Independent from the MLE without binning by force, the rates k 1 and k 2 at each force were obtained by a two-exponential MLE on events binned by force (as in Fig. 5b ) and plotted as data points in Fig. 5c . The later analysis method validates the existence of the two underlying force-dependent rates since it does not assume the Arrhenius equation, yet the resulting data points do indeed follow the equation (Fig. 5c ).
Fitting to Model 1 or Model 2 gave very similar results for k 01 , δ 1 , k 02 , δ 2 , and A (Supplementary Table 2 ). Since log-likelihoods were almost identical from the two models, our data are consistent with both and cannot distinguish between them. To test the significance of the nonzero δ 2 , a likelihood ratio (LR) test was performed, comparing fitting with fixed δ 2 = 0 vs. free δ 2 . In both models and across different concentrations of OM, LR tests gave P values < 1 × 10 -16 , rejecting the null hypothesis of δ 2 = 0. Furthermore, force-binned fitting with two rates and an amplitude value clearly showed a nonflat curve for the slower rate k 2 (Fig. 5c) . Similarly, LR tests of nonzero δ in the single-exponential fitting ( . At 30 nM OM, the number of events from the slow population was not sufficiently large for an accurate fitting. Therefore, for the 30 nM OM data point only ( Fig. 5e-g ), we fixed k 01 = 105 s −1 and δ 1 = 1.16 nm (the weighted means of the rest of the OM concentrations data) and performed the MLE to obtain k 02 , δ 2 , and A. Indeed, the fit produced A = 0.95, confirming that there were very few events in the slow population.
Calculations of duty ratio, average force, and average power. The duty ratio is the time myosin spends in the strongly bound state, t s , divided by the time of its entire cycle, t c . The entire cycle is made up of time in the strong and weak states, t s and t w , respectively. The duty ratio as a function of load force F can be expressed as where k attach describes the lifetime of the weak binding state and is assumed to be independent of force, since myosin cannot yet sense any load on actin when unbound. k attach cannot be determined by directly measuring the lifetimes of the unbound state in the optical trap, because there, the rate of attachment is sensitive to the positions of the actin dumbbell and myosin. However, k attach can be calculated by
where k cat is the overall cycle rate measured by steady state ATPase. Myosin produces an equal and opposite force against the load force, F, up to the isometric force. Thus, average force is the load force multiplied by the duty ratio (equation (4); Fig. 7b ). The maximum value of the x axis in Fig. 7 is the isometric force, taken to be 6 pN 12 .
In the calculation of average power (equation (5)), a constant step size, d, may be a simplification, as some perturbations may alter it (see Supplementary Note). Nevertheless, it is illustrative to calculate the power produced by single myosins to understand the effects of changes to the detachment rate.
Calculations are given by equations (2)-(5) using values in Table 1 
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Sample size
A handful of molecules per condition as detailed in the manuscript and in Extended Data Table 1 . Most conditions have ~5 molecules as that was sufficient to see differences between conditions. WT has 36 molecules because we always measured a WT control for each condition. Similarly, DMSO had also a higher number of molecules.
Data exclusions A few molecules were excluded from analysis because their number of events were too few to determine accurate rates (eg less than 200 events)
Replication
Data was taken on multiple molecules for each condition (Extended Data 
